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Abstract
Background Defects of articular cartilage are an unsolved problem in
orthopaedics. In the present study, we tested the hypothesis that gene
transfer of human fibroblast growth factor 2 (FGF-2) via transplantation
of encapsulated genetically modified articular chondrocytes stimulates
chondrogenesis in cartilage defects in vivo.
Methods Lapine articular chondrocytes overexpressing a lacZ or a human
FGF-2 gene sequence were encapsulated in alginate and further characterized.
The resulting lacZ or FGF-2 spheres were applied to cartilage defects in the
knee joints of rabbits. In vivo, cartilage repair was assessed qualitatively and
quantitatively at 3 and 14 weeks after implantation.
Results In vitro, bioactive FGF-2 was secreted, leading to a significant
increase in the cell numbers in FGF-2 spheres. In vivo, FGF-2 continued to
be expressed for at least 3 weeks without leading to differences in FGF-2
concentrations in the synovial fluid between treatment groups. Histological
analysis revealed no adverse pathologic effects on the synovial membrane
at any time point. FGF-2 gene transfer enhanced type II collagen expression
and individual parameters of chondrogenesis, such as the cell morphology
and architecture of the new tissue. Overall articular cartilage repair was
significantly improved at both time points in vivo.
Conclusions The data suggest that localized overexpression of FGF-2
enhances the repair of cartilage defects via stimulation of chondrogenesis,
without adverse effects on the synovial membrane. These results may lead to
the development of safe gene-based therapies for human articular cartilage
defects. Copyright  2005 John Wiley & Sons, Ltd.
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Introduction
Adult articular cartilage has a very limited capacity for repair [1,2]. Cartilage
defects that penetrate the underlying subchondral bone, such as resulting
from direct trauma, are initially repopulated with mesenchymal cells from
the bone marrow [3]. Over time, many of these pluripotent cells differenti-
ate into chondrocytes, and deposit a cartilaginous matrix [3]. The repair tissue
Copyright  2005 John Wiley & Sons, Ltd.
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that results from that chondrogenesis has inferior
structural characteristics and degenerates over the course
of some months [2]. If let untreated, such cartilaginous
lesions may further progress and eventually lead to
osteoarthritis of the affected joint. An imbalance of
polypeptide growth factors acting upon the cells that
initially repopulate the defect is thought to play an
important role in these events [4]. Consequently,
chondrogenesis might be enhanced by regenerative
signals provided to the site of articular cartilage repair.
Fibroblast growth factor 2 (FGF-2), a member of the
multifunctional fibroblast growth factor family [5,6],
is mitogenic for articular chondrocytes [7,8]. In vivo,
FGF-2 stimulates the differentiation of mesenchymal
cells during chondrogenesis [9,10] and has been
reported to improve the repair of cartilage defects
[11–16]. However, FGF-2 protein has a very short
plasma half-life [14,17] and is rapidly cleared from
the synovial fluid [18]. To achieve a physiological effect
of the protein, either high doses [11,13] or continuous
delivery via osmotic pumps [14,15] are required. Recent
investigations have suggested that gene transfer may be
an alternative to directly produce therapeutic factors at
sites of articular cartilage damage [19,20]. Transgenes
have been expressed in cartilage defects either by
transplantation of chondrocytes genetically modified
using nonviral [21] or viral vectors [22–25], or by
direct vector application [26]. When alginate spheres
carrying transfected chondrocytes were transplanted into
articular cartilage defects, transgene expression persisted
for at least 32 days in vivo [21]. Nonviral, lipid-mediated
overexpression of human FGF-2 was already shown
to selectively stimulate cell proliferation in a model
of articular chondrocyte transplantation in vitro [27].
However, it remains unknown if bioactive FGF-2 can
be secreted from alginate spheres containing transfected
chondrocytes. It also remains unknown if transplantation
of these spheres to sites of articular cartilage damage
would modulate the chondrogenesis and cartilage repair
in vivo in a safe manner. In the present study, we tested the
hypothesis that lipid-mediated overexpression of human
FGF-2 via transplantation of alginate spheres containing
genetically modified articular chondrocytes enhances
chondrogenesis and stimulates articular cartilage repair
in vivo. To determine the effects of FGF-2 overexpression
at the beginning of chondrogenesis [3], a first time point of
3 weeks after transplantation was chosen for evaluation.
Since the repair tissue begins to degenerate by 12 weeks
in this model system [3], a second time point of 14 weeks
was selected to evaluate the long-term effects of FGF-2
overexpression on articular cartilage repair.
Materials and methods
Materials
Plasticware was obtained from Falcon (Becton Dick-
inson, Pont de Claix, France). All reagents were
from Invitrogen/GIBCO (Karlsruhe, Germany) unless
otherwise noted. Bovine testicular hyaluronidase, L-
cystein, Na2ETDA, calf thymus DNA and alginate were
from Sigma (Munich, Germany). Collagenase type I (activ-
ity: 232 U/mg) was from Biochrom (Berlin, Germany).
Dimethylmethylene blue was from Serva (Darmstadt, Ger-
many). Chondroitin-6-sulfate from shark cartilage was
purchased from Fluka (Buchs, Switzerland).
Cell culture and lipid-based
transfection
Articular cartilage was harvested from the knee and hip
joints of three male Chinchilla bastard rabbits (mean
weight: 1.9 ± 0.2 kg; Charles River, Sulzfeld, Germany).
The cartilage was washed twice with phosphate-buffered
saline (PBS), diced into 2.0 × 2.0 × 0.5 mm fragments,
and digested in spinner bottles containing Dulbecco’s
modified Eagle’s medium (DMEM) with 50 µg/ml ascorbic
acid, 100 U/ml penicillin G, 100 µl/ml streptomycin
(basal medium) and 0.02% collagenase in a humidified
atmosphere with 10% CO2 at 37 ◦C for 16 h. Isolated
cells were filtered through a 125 µm mesh to remove
undigested matrix. Viability was determined by trypan
blue exclusion and always exceeded 90%. The cell number
was determined by hemocytometry.
Isolated chondrocytes were placed in monolayer culture
in 100-mm dishes in basal medium containing 10%
fetal bovine serum (growth medium). Transfections
were performed with subconfluent cells, 10–14 days
after cell isolation, using endotoxin-free expression
plasmid vectors carrying either the E. coli lacZ gene
(pCMVlacZ; termed lacZ-transfected), or a human FGF-
2 cDNA (pCMVhFGF-2; termed FGF-2-transfected) [27]
placed under the control of the human cytomegalovirus
(CMV) immediate-early promoter/enhancer and the
nonliposomal lipid formulation FuGENE 6 (Roche Applied
Sciences, Mannheim, Germany), as previously described
[21]. Aliquots of chondrocytes used for the production
of alginate spheres were processed for X-gal staining
and demonstrated a mean transfection efficiency of
42.1 ± 3.0%, consistent with previous data using this
technique [21].
Encapsulation of transfected and
non-transfected chondrocytes in
alginate spheres
One day after transfection, lacZ- and FGF-2-transfected
chondrocytes were encapsulated in alginate as previously
described [21]. Briefly, transfected chondrocytes were
suspended in 1.2% alginate in 0.15 M NaCl at a density of
4 × 106 cells/ml. The cell suspension was then extruded
through a 21-gauge needle (Braun, Melsungen, Germany)
into 102 mM CaCl2 at room temperature under constant
shaking and allowed to polymerize for 10 min. The
resulting alginate spheres containing lacZ- or FGF-2-
transfected chondrocytes (termed lacZ or FGF-2 spheres)
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were washed twice in 0.15 M NaCl, followed by two
washes in basal medium, and then placed in 96-well
plates (one sphere/well) containing basal medium that
was changed three times per week and kept at 37 ◦C in a
humidified atmosphere of 10% CO2. At days 0, 1, 3, 7, 14,
21 and 28 post-encapsulation, individual spheres were
dissolved in 100 µl 55 mM sodium citrate, 90 mM NaCl,
pH 6.8, for 20 min at room temperature and submitted
to further analysis. Spheres composed of non-transfected
chondrocytes were individually cultured in basal medium
without or with the addition of 5 ng/ml recombinant FGF-
2 (PeproTech, London, UK) or in growth medium. For
these experiments, the complete medium was replaced
every other day.
Cell counts and glycosaminoglycan
content of alginate spheres
Released chondrocytes were counted and their viability
was determined using a Neubauer chamber and try-
pan blue exclusion staining based on four counts per
sample. For glycosaminoglycan analysis, released chon-
drocytes were incubated overnight in 125 µg/ml papain
in PBE containing 10 mM Na2ETDA. Glycosaminogly-
cans were measured spectrophotometrically by binding
to the dimethylmethylene blue dye, using chondroitin-6-
sulfate as a standard [28]. Absorbance was monitored at
530 nm. Measurements were performed using a GENios
spectrophotometer/fluorometer (Tecan, Crailsheim, Ger-
many).
Transplantation of alginate spheres to
osteochondral cartilage defects in vivo
The transplantation of spheres in vivo was performed
on the day of encapsulation (1 day post-transfection).
All animal procedures were approved by the Saarland
Governmental Animal Care Committee. Chinchilla bastard
rabbits (Charles River) were kept in air-conditioned rooms
with constant temperatures and a regular light/dark
scheme. They received water ad libitum and were
fed a standard diet. Fourteen female rabbits (mean
weight: 2.9 ± 0.3 kg; seven animals per group) were
anesthetized by intramuscular injection of Rompun
(0.2 ml/kg body weight; Bayer, Leverkusen, Germany)
and Ketavet (0.75 mg/kg body weight; Pharmacia &
Upjohn, Erlangen, Germany). The knee joint was entered
using a medial parapatellar approach. The patella was
dislocated laterally and the knee flexed to 90◦. A
cylindrical osteochondral defect was created in the
patellar groove of each knee (n = 28 defects) with a
manual cannulated burr (3.2 mm in diameter; Synthes,
Umkirch, Germany). The defects were washed with
PBS to remove debris and blotted dry. Spheres (from
a single preparation, Table 1) were press-fit into the
defects. The right and left knees alternately received
lacZ or FGF-2 spheres. The patella was reduced and the
knee was put through a range of motion to assure the
stability of the spheres. Incisions were closed in layers.
Immediately postoperatively, animals were allowed full
weight bearing without any immobilization. Animals
were allowed to climb and jump 6 weeks after the
implantation.
Detection of transgene expression
Detection of β-galactosidase activity was performed
by X-gal staining using a standard protocol [21].
To measure the production of FGF-2 by transfected
chondrocytes encapsulated in alginate, the spheres
were individually cultivated in 96-well plates (one
sphere/well) in growth medium. At the indicated time
points, spheres were washed twice in basal medium and
the medium was replaced with 200 µl basal medium.
After 24 h, the conditioned medium was collected.
To monitor the FGF-2 content in the synovial fluid,
knees received a lavage with 1 ml PBS. All samples
were centrifuged to remove cell debris and stored at
−80 ◦C. Samples were analyzed using a FGF-2 enzyme-
linked immunosorbent assay (ELISA) (R&D Systems,
Wiesbaden, Germany) with a detection limit of 3
pg/ml.
Histological and immunohistochemical
analysis
Spheres cultured in vitro were fixed in 4% phosphate-
buffered formalin, embedded in paraffin, sectioned
Table 1. FGF-2 production by chondrocyte-alginate spheres in vitro
Day post-transfection
Day post-encapsulation
1
0
2
1
4
3
8
7
15
14
22
21
29
28
lacZ spheres
FGF-2 (ng/107 viable cells/24h) 0.5 ± 0.2 0.5 ± 0.1 0.1 ± 0.1 0.4 ± 0.0 0.7 ± 0.6 0.5 ± 0.4 0.2 ± 0.1
FGF-2 (pg/sphere/24 h) 2.4 ± 0.8 2.7 ± 0.2 0.2 ± 0.2 1.9 ± 0.1 3.4 ± 2.8 2.6 ± 2.0 0.7 ± 0.4
FGF-2 spheres
FGF-2 (ng/107 viable cells/24 h) 41.1 ± 0.5 47.4 ± 1.0 17.7 ± 2.1 10.7 ± 3.5 1.3 ± 0.3 4.2 ± 2.9 2.0 ± 0.2
FGF-2 (pg/sphere/24 h) 210.4 ± 1.7 210.7 ± 0.4 77.0 ± 14.4 48.5 ± 14.8 7.6 ± 2.0 27.0 ± 21.0 11.4 ± 0.5
Lapine articular chondrocytes transfected with pCMVlacZ or pCMVhFGF-2 were encapsulated in alginate on day 1 post-transfection and kept in basal
medium for 28 days. Conditioned medium was collected at the denoted times and FGF-2 protein concentrations were measured by ELISA. Data are
expressed as mean ± standard deviation (S.D.) (n = 2 for each time point and condition).
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and submitted to histological and immunohistochemical
analysis as described below. Three (n = 7) and 14 weeks
(n = 7) after implantation, rabbits were euthanized
with pentobarbital (150 mg/kg body weight; Merial,
Hallbergmoos, Germany) and the knee joints were
exposed and examined for synovitis, osteophytes, or other
reactions. The appearance of the defect (color, integrity,
contour) and the articulating surfaces were documented.
Distal femurs were retrieved, fixed in 4% phosphate-
buffered formalin, trimmed, and decalcified. Paraffin-
embedded frontal sections (5 µm) were stained with
safranin-O and hematoxylin and eosin (H&E) according
to routine histological protocols [29]. For FGF-2, type
II and type I collagen immunostaining, deparaffinized
sections were submerged for 30 min in 0.3% hydrogen
peroxide. After washing with PBS and incubation in 0.1%
trypsin for 30 min, sections were washed with PBS and
blocked with 3% bovine serum albumin in PBS (blocking
buffer) for 30 min. The sections then were incubated
with a 1 : 100 dilution of a monoclonal mouse anti-
FGF-2 IgG (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or with a 1 : 50 dilution of a monoclonal mouse
anti-type-II or anti-type-I collagen IgG (Acris Antibodies,
Hiddenhausen, Germany) in blocking buffer for 24 h at
4 ◦C, washed and exposed to a 1 : 500 dilution of a
biotinylated anti-mouse antibody (Vector Laboratories,
Gru¨nberg, Germany) for 1 h at room temperature.
After washing with PBS, the sections were incubated
for 30 min with the avidin-biotin-peroxidase reagent
(Vectastain Elite ABC kit; Vector Laboratories), washed,
and exposed to diaminobenzidine (Vector Laboratories).
To control for secondary immunoglobulins, sections
were processed as above, except for the secondary
antibody.
Evaluation of histological sections
The synovial membrane was evaluated using a previously
published scoring system [30,31]. The categories of
the score include villus thickening (fibrosis), villus
architecture (blunting), and the presence of inflammatory
cell infiltrates. The area occupied by lacZ and FGF-2
spheres in the defects was measured on H&E-stained
serial histological sections of the distal femora that were
taken within approximately 0.6 mm from the center of
the defects at 200 µm intervals (n = 3–5 per defect).
Low-magnification images of the cartilage defects were
acquired by a solid-state CCD camera mounted on a
BX-45 microscope (Olympus, Hamburg, Germany). The
image on the monitor was digitalized and the border
of the sphere of each section was traced by a blinded
observer. The area of the sphere was calculated with
the analySIS program (Soft Imaging System, Mu¨nster,
Germany). Immunoreactivity to type II collagen in the
repair tissue was compared with that of the adjacent
normal articular cartilage which served as a positive
internal control. Immunoreactivity to type I collagen
in the repair tissue was compared to that of the
subchondral bone adjacent to the normal articular
cartilage which served as a positive internal control. A
score was given to each knee: −, no immunoreactivity; +,
weaker immunoreactivity; ++, similar immunoreactivity;
+++, stronger immunoreactivity. For the quantitative
assessment of the repair tissue, serial histological
sections of the distal femora were taken at 200 µm
intervals. Sections within approximately 1.0 mm from
the center of the defect (n = 9–10 per defect) were
analyzed using the articular cartilage repair scoring
system described by Sellers and co-workers [32,33].
Specific parameters that were evaluated include filling
of the defect, integration of the new cartilage, safranin
O staining, cell morphology, architecture within the
defect and of its surface, restoration of the subchondral
bone and tidemark. Scores were combined and resulted
in an average total score. Values range from 31
points (empty defect without repair tissue) to 0 points
(normal articular cartilage, complete regeneration). A
total of 274 sections were independently scored by
three individuals without knowledge of the treatment
groups.
Statistical analysis
Each test condition was performed in duplicate for the
in vitro characterization experiments and with seven
defects per group and time point for the in vivo
experiments. Differences in cell number, viability and
glycosaminoglycan content were compared between
treatment and control groups using nested analysis
of variance (ANOVA). To determine the sample size
for the in vivo experiments, a standard deviation of
25% for the mean total score was estimated based on
literature values for selected cartilage repair procedures.
For a power of 80% (beta = 0.20) and a two-tailed
alpha level of 0.05, a sample size of six animals per
group would have been sufficient to detect a mean
difference of 5 points between the groups, assuming
a pooled standard deviation of 2.5 points [effect
size = 5/2.5 = 2.0, using the two-sample Student’s t-
test (version 5.0, nQuery Advisor, Statistical Solutions,
Saugus, MA, USA)]. To evaluate the in vivo experiments,
points for each category and total score were compared
between the two groups using a mixed general linear
model with repeated-measures (knees nested within the
same animals). All continuous variables, including FGF-
2 production and histological scoring for parameters
such as cell morphology, architecture and tidemark,
were tested for normality using the Kolmogorov-Smirnov
goodness-of-fit method and no significant skewness or
kurtosis was detected. Therefore, continuous data are
expressed in terms of the mean ± standard deviation
(S.D.) or mean ± 95% confidence interval. A two-
tailed P < 0.05 was considered statistically significant.
Statistical analysis of the data was performed using the
SPSS software package (version 12.0, SPSS Inc., Chicago,
IL, USA).
Copyright  2005 John Wiley & Sons, Ltd. J Gene Med 2006; 8: 100–111.
104 G. Kaul et al.
Results
Human FGF-2 is efficiently released
from alginate spheres over a prolonged
period of time in vitro
The ability of the alginate spheres to release the
recombinant factor produced by the encapsulated cells is a
prerequisite for the localized delivery of the gene product
to cartilage defects in vivo. Accordingly, we transfected
lapine articular chondrocytes with expression plasmid
vectors carrying either the E. coli lacZ gene or a human
FGF-2 cDNA, using the nonliposomal lipid preparation
FuGENE 6. One day after transfection, the modified
chondrocytes were encapsulated in alginate. The resulting
lacZ and FGF-2 spheres were kept in culture for 28 days
and the course of FGF-2 secretion was assessed over time.
In vitro, maximal FGF-2 production of FGF-2 spheres was
47.4 ± 1.0 ng/107 viable chondrocytes/24 h at day 2 after
transfection, 95-fold higher compared to lacZ spheres
(P < 0.001, n = 2) (Table 1). After 28 days in vitro, FGF-2
production of FGF-2 spheres was 2.0 ± 0.2 ng/107 viable
chondrocytes/24 h, 10-fold higher than in lacZ spheres
(P = 0.006, n = 2).
Overexpression of human FGF-2
stimulates chondrocyte proliferation
but not glycosaminoglycan synthesis in
alginate spheres in vitro
Next, the biological effects of human FGF-2 overexpres-
sion on the encapsulated chondrocytes were investigated.
At different time points in vitro, viability, cell number and
glycosaminoglycan content in the spheres were deter-
mined. At the time of encapsulation, the chondrocytes in
the lacZ and FGF-2 spheres had a viability of 89.0 ± 1.4%
and 91.5 ± 0.7%, respectively (P > 0.05, n = 2). Cell via-
bility remained above 80% in all spheres at all other time
points (data not shown). At day 29 post-transfection,
the viability of the chondrocytes in the lacZ and FGF-
2 spheres was similar compared to day 1 (84.9 ± 2.4%
and 89.0 ± 1.7%, respectively; P > 0.05, n = 10). The
number of viable chondrocytes in the lacZ and FGF-2
spheres was similar at the time of encapsulation, 1 day
post-transfection (4.9 ± 0.2 × 104 and 5.1 ± 0.1 × 104
cells/sphere, respectively; P > 0.05, n = 2). At day 29
post-transfection, the number of viable chondrocytes
in lacZ spheres increased by 25.5% to 6.2 ± 0.8 × 104
cells/sphere, without reaching statistical significance
when compared to day 1 (P > 0.05, n = 10). In contrast,
FGF-2 spheres contained 7.1 ± 0.4 × 104 cells/sphere,
significantly more when compared to lacZ spheres at
this time point (P < 0.001, n = 10). This corresponds to
a 39.2% increase (P = 0.008, n = 10) in the number of
viable chondrocytes in FGF-2 spheres between days 1 and
29 post-transfection. At day 29, the glycosaminoglycan
content of FGF-2 spheres was not different from that
of lacZ spheres (8.17 ± 0.84 and 8.46 ± 1.09 µg/sphere,
respectively; P > 0.05, n = 8).
Exogenous FGF-2 stimulates the
proliferation of chondrocytes in
alginate spheres in vitro
In order to compare the increase in cell proliferation as
a result of FGF-2 overexpression to that obtained after
exposure to exogenous FGF-2 protein, non-transfected
chondrocytes encapsulated in alginate were incubated
in basal medium without or with 5 ng/ml FGF-2 or in
growth medium (as a positive control) for 28 days. At
the time of encapsulation, chondrocytes had a viability of
88.0 ± 4.5% and a total viable cell number of 5.9 ± 0.6 ×
104 cells/sphere. After the 28-day incubation in basal
medium, cell viability was 84.1 ± 2.4% and the number
of viable chondrocytes was 6.1 ± 0.4 × 104 cells/sphere.
This corresponds to a 3.4% increase in the number of
viable cells, not significantly different compared to day 0
(P > 0.05 for viability and number of viable chondrocytes
in comparison to day 0, n = 10). Continuous exposure to
5 ng/ml exogenous FGF-2 led to a cell viability of 89.0 ±
1.3% and to 7.9 ± 1.1 × 104 viable chondrocytes/sphere
after 28 days. This corresponds to a 33.9% increase
in the number of viable chondrocytes compared to
day 0 (P < 0.01, n = 10). When chondrocyte-alginate
spheres were continuously exposed to growth medium,
chondrocyte viability was 90.0 ± 1.3% and the number
of viable chondrocytes was 8.5 ± 0.7 × 104 cells/sphere
at day 28. This corresponds to a 44.1% increase in the
number of viable chondrocytes (P = 0.01, n = 10). A
comparison of the different culture conditions at day 28
after encapsulation revealed no significant differences in
cell viability and in the number of viable chondrocytes
between spheres incubated in basal medium containing
5 ng/ml FGF-2 or in growth medium (P < 0.05, n = 10
spheres). Compared with spheres incubated in basal
medium alone, chondrocyte viability and the number
of viable cells were significantly higher (P < 0.01, n = 10
spheres) in spheres incubated in 5 ng/ml FGF-2 or in
growth medium. Thus, the 39.2% increase following FGF-
2 overexpression is well comparable to the 33.9% increase
following continuous exposure to 5 ng/ml exogenous
FGF-2 protein in vitro.
Localized human FGF-2 gene transfer
does not induce a synovial
inflammatory response in vivo
On the day of encapsulation, lacZ or FGF-2 spheres were
press-fit into osteochondral defects in each patellar groove
of 14 rabbits. Three and 14 weeks following implantation,
there were no macroscopic signs of inflammation or
hematoma. FGF-2 concentrations were monitored in
the lavage fluid of knees. After 3 weeks, there was no
difference between knees receiving lacZ or FGF-2 spheres
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Table 2. Effects of FGF-2 gene transfer at 3 and 14 weeks in vivo
on histological grading of the synovium
Category lacZ spheres FGF-2 spheres P value
3 weeks
Villus thickening 0.43 ± 0.50 0.46 ± 0.51 >0.05
Villus architecture 0.29 ± 0.46 0.25 ± 0.44 >0.05
Inflammatory cell infiltrate 0.11 ± 0.31 0.14 ± 0.36 >0.05
Average total score 0.82 ± 0.16 0.86 ± 0.16 >0.05
14 weeks
Villus thickening 0.14 ± 0.36 0.14 ± 0.36 >0.05
Villus architecture 0.29 ± 0.49 0.21 ± 0.43 >0.05
Inflammatory cell infiltrate 0.00 ± 0.00 0.14 ± 0.36 >0.05
Average total score 0.43 ± 0.14 0.50 ± 0.04 >0.05
Each category or total score is calculated as the average score performed
by two independent evaluators. Points for each category and total score
were compared between the FGF-2 and lacZ groups using ANOVA. Data
are expressed as mean ± S.D.
(24.3 ± 23.6 and 21.5 ± 13.0 pg/ml, respectively; P >
0.05, n = 7). Similar results were obtained after 14 weeks
in vivo (66.7 ± 55.6 and 58.0 ± 25.7 pg/ml, respectively;
P > 0.05, n = 7). We next investigated the effects of the
recombinant human FGF-2 overexpression on the synovial
membrane using a previously published score. Analysis of
the thickness, architecture of synovial villi, and presence
of inflammatory cell infiltrates revealed no significant
differences between knees receiving lacZ or FGF-2 spheres
at either 3 or 14 weeks (P > 0.05 for both time points,
n = 7) (Table 2; Figures 2 and 3L– 3M).
Alginate spheres containing genetically
modified chondrocytes produce FGF-2
for at least 3 weeks in vivo and are
progressively resorbed
Over the course of the in vivo experiment, the spheres
remained underneath the original articular cartilage
(Figures 2 and 3A, 3B). After 3 weeks, both lacZ and
FGF-2 spheres were surrounded and in part invaded
by a resorptive tissue consisting of undifferentiated
mesenchymal cells, histiocytotic cells and lymphocytes
(Figure 1A and 1B). FGF-2 expression was detected by
immunohistochemistry in FGF-2 spheres (Figure 1F). The
areas occupied by lacZ and FGF-2 spheres after 3 weeks
were 1.62 ± 1.23 and 1.14 ± 0.63 mm2, respectively (P >
0.05, n = 7). After 14 weeks, remnants of the spheres
were detectable in the newly formed subchondral bone
(Figures 1C and 1D). Spheres were surrounded by a
loose reparative tissue that consisted of fibroblasts and
histiocytes, consistent with remnants of a resorptive
granulation tissue. The areas occupied by lacZ and
FGF-2 spheres were 0.03 ± 0.05 and 0.08 ± 0.13 mm2,
respectively (P > 0.05, n = 3). Between 3 and 14 weeks,
the spheres were progressively resorbed, as indicated by
a significant decrease in their area (P < 0.0001 for both
groups).
Figure 1. Representative histological sections of lacZ (A, C,
E) and FGF-2 spheres (B, D, F) after 3 (A, B, E, F) and
14 weeks (C, D) in vivo stained with safranin O (A–D) and a
monoclonal mouse anti-human FGF-2 IgG. At 3 weeks, spheres
were surrounded and in part invaded by a resorptive tissue (A,
B). FGF-2 was expressed in FGF-2 spheres (F). After 14 weeks,
only remnants of the spheres were detectable, which were
surrounded by a resorptive granulation tissue (C, D). Original
magnification ×200 (A–D) and ×250 (E, F)
Effect of localized human FGF-2 gene
transfer on type II and type I collagen
synthesis at 3 and 14 weeks in vivo
The new tissue in the cartilage defects was analyzed
by immunohistochemistry for the presence of type
II collagen, a major component of the extracellular
matrix of hyaline articular cartilage. Three weeks after
transplantation, immunoreactivity to type II collagen was
weaker in the repair tissue of defects that received
lacZ spheres than in those where FGF-2 spheres were
applied (Table 3; Figures 2G and 2H). Fourteen weeks
after transfection, immunoreactivity to type II collagen in
defects receiving lacZ spheres was less than or similar to
that of the adjacent normal articular cartilage (Table 3;
Figures 3G and 3H). All defects receiving FGF-2 spheres
exhibited immunoreactivity to type II collagen similar to
that of the adjacent normal articular cartilage. The new
tissue was then analyzed by immunohistochemistry for the
presence of type I collagen, an indicator of fibrocartilage.
Three weeks after transplantation, immunoreactivity to
type I collagen was stronger in the repair tissue of
defects that received lacZ spheres than in those where
FGF-2 spheres were applied (Table 4; Figures 2I– 2K).
Fourteen weeks after transfection, immunoreactivity to
type I collagen decreased in defects of both groups, while
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Figure 2. Stimulation of chondrogenesis in articular cartilage defects 3 weeks after transplantation of genetically modified
chondrocytes in vivo. Histological appearance of osteochondral defects following treatment with a lacZ (A, C, E, G, I, L) or a FGF-2
sphere (B, D, F, H, K, M) stained with safranin O (A–D), hematoxylin and eosin (H&E) (E, F), a monoclonal mouse anti-human
type-II collagen IgG (G, H), or a monoclonal mouse anti-human type I collagen IgG (I, K). Images (L) and (M) depict the synovial
membrane adjacent to the cartilage (H&E). Images (C) and (D) are magnified views of images (A) and (B) illustrating the area of
integration between the repair tissue (left-hand side of each picture) with the adjacent normal articular cartilage (right-hand side of
each picture). Spheres remained in a subchondral location and are visible at the bottom of images (A) and (B). Safranin O staining
was increased in defects receiving a FGF-2 sphere (B, D). Cells in the repair tissue of the osteochondral defect following treatment
with a lacZ sphere were spindle-shaped, indicative of a fibrous repair tissue (C, E). In contrast, cells in the new tissue in the defect
following treatment with a FGF-2 sphere were round and had round nuclei, thus exhibiting characteristics of chondrocytes (D, F).
Immunoreactivity to type II collagen was already present in the repair tissue of the defect receiving a FGF-2 sphere (H). Sections
were taken from defects having a histological rating equal to the mean score for its respective treatment group. Photomicrographs
were obtained using standardized photographic parameters, including light intensity. Original magnifications ×40 (A, B) or ×100
(C–M)
Table 3. Semiquantitative analysis of type II collagen immunore-
activity in the repair tissue 3 and 14 weeks in vivo
3 weeks 14 weeks
Animal
number lacZ spheres FGF-2 spheres lacZ spheres FGF-2 spheres
1 + ++ + ++
2 ++ ++ ++ ++
3 + ++ ++ ++
4 ++ + ++ ++
5 − ++ ++ ++
6 − +++ + ++
7 ++ + ++ ++
Range − to ++ + to +++ + to ++ ++
Type II collagen immunoreactivity in the repair tissue of the defect was
compared to that of the normal articular cartilage adjacent to the defect,
used as a positive internal control. Type II collagen immunoreactivity was
scored as follows: −, no immunoreactivity; +, weaker immunoreactivity;
++, similar immunoreactivity; +++, stronger immunoreactivity.
it continued to be stronger in defects that received lacZ
spheres (Table 4; Figures 3I– 3K).
Localized human FGF-2 gene transfer
stimulates chondrogenesis at 3 and
14 weeks in vivo
To study the effects of FGF-2 overexpression on articular
cartilage repair in vivo, the newly formed repair tissue
within the defect was evaluated using a previously
published grading system [32,33] that consists of eight
individual parameters. First, the animal model was
validated to confirm the absence of a complete cartilage
regeneration. The development over time of the new
tissue was determined for defects treated with lacZ
spheres. A comparison for defect healing of the lacZ
control group between 3 and 14 weeks in vivo revealed
a significantly better healing at 14 weeks with respect to
filling of the defect (P < 0.01), architecture within the
defect (P < 0.05), and average total score (P < 0.01),
indicating a maturation of the repair tissue over time. In
parallel, signs of degradation of the repair tissue were
evident after 14 weeks in vivo, indicated by a higher
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Figure 3. Stimulation of chondrogenesis in articular cartilage defects 14 weeks after transplantation of genetically modified
chondrocytes in vivo. Histological appearance of osteochondral defects following treatment with a lacZ (A, C, E, G, I, L) or a FGF-2
sphere (B, D, F, H, K, M) stained with safranin O (A–D), hematoxylin and eosin (H&E) (E, F), a monoclonal mouse anti-human
type II collagen IgG (G, H), or a monoclonal mouse anti-human type I collagen IgG (I, K). Images (L) and (M) depict the synovial
membrane adjacent to the cartilage (H&E). Images (C) and (D) are magnified views of images (A) and (B). Safranin O staining is
increased in the defect receiving a FGF-2 sphere (B, D) compared to the defect receiving a lacZ sphere. Cells in the repair tissue of
both defects were round and had round nuclei (C–F). However, only cells in the defect treated with a FGF-2 sphere were oriented
in a columnar fashion (F). Immunoreactivity to type II collagen was reduced in the repair tissue of the defect receiving a lacZ
sphere (G). Sections were taken from defects having a histological rating equal to the mean score for its respective treatment group.
Photomicrographs were obtained using standardized photographic parameters, including light intensity. Original magnifications
×40 (A, B) or ×100 (C–M)
(lower) score value for both the surface of the new tissue
and the tidemark compared to 3 weeks (Tables 5 and 6).
Subsequently, articular cartilage repair was compared
for defects receiving lacZ or FGF-2 spheres 3 and 14 weeks
after implantation. No complete articular cartilage
Table 4. Semiquantitative analysis of type I collagen immunore-
activity in the repair tissue 3 and 14 weeks in vivo
3 weeks 14 weeks
Animal
number lacZ spheres FGF-2 spheres lacZ spheres FGF-2 spheres
1 − + + +
2 + + − −
3 + − ++ −
4 + ++ − −
5 − − − −
6 ++ − + −
7 ++ − − −
Range − to ++ − to ++ − to ++ − to +
Type I collagen immunoreactivity in the repair tissue of the defect was
compared to that of the subchondral bone adjacent to the normal
articular cartilage, used as a positive internal control. Type I collagen
immunoreactivity was scored as follows: −, no immunoreactivity; +,
weaker immunoreactivity; ++, similar immunoreactivity; +++, stronger
immunoreactivity.
regeneration (0 points) was achieved at both time points
for defects treated with lacZ and FGF-2 spheres. However,
after 3 weeks, the defects receiving FGF-2 spheres were
Table 5. Effects of FGF-2 gene transfer at 3 weeks on histological
grading of the repair tissue
Category
lacZ spheres
Mean (95% CI)
FGF-2 spheres
Mean (95% CI) P value
Filling of the defect 2.00 (0.83–3.17) 0.77 (0.27–1.27) < 0.01∗∗
Integration 1.50 (0.81–2.19) 1.41 (1.02–1.81) 0.25
Matrix staining 2.91 (2.51–3.32) 2.14 (0.79–3.50) 0.07
Cell morphology 2.96 (2.00–3.91) 2.29 (1.59–2.98) 0.12
Architecture within the
defect
2.16 (1.27–3.04) 1.67 (1.20–2.15) <0.01∗∗
Architecture of the
surface
1.64 (0.79–2.50) 1.52 (1.11–1.95) 0.47
Subchondral bone 2.23 (0.96–3.50) 1.83 (1.03–2.63) 0.59
Tidemark 3.84 (3.56–4.12) 3.54 (2.79–4.29) 0.11
Average total score 19.1 (15.6–22.6) 15.2 (11.6–18.8) <0.01∗∗
Each category or total score is based on the average of three
independent evaluators. Points for each category and total score were
compared between the FGF-2 and lacZ groups using a mixed-model
analysis with repeated-measures (knees nested within the same animals;
CI = confidence interval). Means indicate the estimated scores in points
for each category.
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Table 6. Effects of FGF-2 gene transfer at 14 weeks on histologi-
cal grading of the repair tissue
Category
lacZ spheres
Mean (95% CI)
FGF-2 spheres
Mean (95% CI) P value
Filling of the defect 0.48 (0.09–0.87) 0.11 (0.01–0.38) 0.08
Integration 1.33 (0.68–1.98) 1.18 (0.95–1.42) 0.61
Matrix staining 2.52 (1.63–3.41) 1.52 (0.72–2.33) 0.07
Cell morphology 2.60 (1.82–3.38) 1.40 (1.04–1.76) <0.01∗∗
Architecture within the
defect
1.60 (0.90–2.30) 1.18 (0.76–1.61) 0.24
Architecture of the
surface
1.89 (1.30–2.48) 1.57 (1.17–1.97) 0.29
Subchondral bone 1.13 (0.63–1.63) 0.84 (0.21–1.46) 0.39
Tidemark 4.00 (4.00–4.00) 3.30 (2.79–3.81) <0.01∗∗
Average total score 15.8 (13.3–18.2) 11.1 (8.9–13.2) <0.01∗∗
Each category or total score is based on the average of three
independent evaluators. Points for each category and total score were
compared between the FGF-2 and lacZ groups using a mixed-model
analysis with repeated-measures (knees nested within the same animals;
CI = confidence interval). Means indicate the estimated scores in points
for each category.
filled with new tissue to a level similar to that of
the surrounding normal articular cartilage (Figure 2B).
This corresponds to the lowest (best) average individual
score value (0.77) of all categories evaluated, 2.6-fold
better than defects receiving lacZ spheres (P < 0.01,
n = 7) (Table 5). Similarly, the individual score value
for architecture of the defect was 1.3-fold improved
for defects receiving FGF-2 spheres compared to those
where lacZ spheres were applied (P < 0.01, n = 7)
(Figures 2D– 2F). At this early time point, the values for
all other individual categories were improved for defects
receiving FGF-2 spheres, compared to those that received
lacZ spheres, although they did not reach statistical
significance. Individual scores were combined and the
resulting average total score was compared between
the two groups using a mixed general linear model of
statistical analysis. The average total score after 3 weeks
was significantly improved for defects receiving FGF-2
spheres compared with defects receiving lacZ spheres
(19.1 vs. 15.2, P < 0.01, n = 7).
After 14 weeks, the morphology of the cells repop-
ulating the defects that received FGF-2 spheres was
significantly improved compared to the control, as noted
by a 1.9-fold better score value (Table 6). This indi-
cates that the cells in the new tissue were mostly
round and predominantly arranged in a columnar fash-
ion, exhibiting characteristics of a chondrocyte phenotype
(Figures 3D– 3F). Re-establishment of the tidemark was
significantly accelerated in the defects receiving FGF-2
spheres, compared to those where lacZ spheres were
implanted. Values for all other individual parameters
were improved for defects receiving FGF-2 spheres com-
pared with the controls, although they did not reach
statistical significance. The average total score after
14 weeks was significantly improved for the defects
receiving FGF-2 spheres, compared with the defects
that received lacZ spheres (15.8 vs. 11.1; P < 0.01,
n = 7).
Discussion
A major challenge of gene therapy for human articular
cartilage defects is to locally and safely deliver and
express the therapeutic transgene. In the present
study, we tested the hypothesis that overexpression
of human FGF-2 via a nonviral gene delivery method
by transplanted articular chondrocytes enhances the
repair of full-thickness cartilage defects in vivo. The data
indicate that FGF-2-transfected chondrocytes embedded
in alginate spheres released functionally active FGF-2 for
at least 1 month in vitro. The secreted factor selectively
stimulated chondrocyte proliferation in spheres in vitro.
The data further suggest that FGF-2 was expressed for at
least 3 weeks in vivowithout leading to differences in FGF-
2 concentrations in the synovial fluid or adverse effects on
the synovial membrane. Finally, the data demonstrate that
transplantation of FGF-2 spheres into cartilage defects
augments specific parameters of chondrogenesis and
results in an enhanced articular cartilage repair for a
period of 14 weeks in vivo.
The delivery of FGF-2 to articular cartilage defects
remains a problem. Studies that applied FGF-2 to articular
cartilage defects by intraarticular injection of the protein
have employed high single doses of 7 × 105 pg [13] or
between 3.6 × 103 [14] and 12 × 103 pg/day [34] via
osmotic pumps for up to 2 weeks. However, FGF-2 protein
has a plasma half-life of less than 1 h and is rapidly cleared
after a few hours of intraarticular administration [18].
The spheres employed in the present study secreted 210
pg FGF-2/sphere/day on day 2 and 11 pg FGF-2/sphere
on day 28. These values are 10- to 100-fold higher than
the 1–2 pg of FGF-2/day secreted by stably transfected
NIH3T3 cells encapsulated in a biocompatible polymer
[35].
FGF-2 has been implicated in many studies as a
modulator of chondrocyte proliferation in vitro [7,8]. In
the present study, the number of viable cells in FGF-2
spheres increased by 39.2% after 28 days in vitro. This
compares favorably with the 33.9% increase obtained
when spheres composed of non-transfected chondrocytes
were continuously exposed to 5 ng/ml exogenous FGF-
2 protein. Thus, the proliferative response of the
encapsulated chondrocytes to FGF-2 overexpression is
relevant. It remains to be determined if the amplitude of
this response may be further increased, for example via
strategies that lead to higher levels of the transcript. The
absence of an effect of FGF-2 on the glycosaminoglycan
content is consistent with the context dependence (e.g.
monolayer vs. three-dimensional cell culture systems) of
the actions of FGF-2. These data are in good agreement
with previous findings [15,27] and suggest that the
recombinant human FGF-2 protein is bioactive and
capable of stimulating chondrocyte mitotic activity.
Alginate spheres can be manufactured to carry a variety
of therapeutic cells [38,39] and have been used in
human studies [40]. We employed alginate as a carrier
for chondrocytes because it allows the safe delivery
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of genetically modified chondrocytes into osteochondral
defects in vivo [21,25] and promotes the expression of
cartilage-specific genes [41,42]. In the present study, the
alginate spheres were progressively resorbed over time.
This removal of the transplanted spheres may be due
to a host reaction against the alginate, the transplanted
allogeneic chondrocytes or the transgene. These findings
are in agreement with other studies [25,43] and suggest
that the main role of the transplanted chondrocytes is
the production of the therapeutic FGF-2, rather than to
participate in the repopulation of the defect.
Local application of chondrocytes secreting human
FGF-2 via spheres to cartilaginous defects may avoid
a potential dilution of the factor in the synovial fluid
and/or its uptake by synovial cells. It may thus prevent the
development of an inflammation of the knee joint. Indeed,
by 3 weeks in vivo there was a sustained production of
FGF-2 by spheres that may have lasted for more than
4 weeks as previously determined using a reporter gene
[21]. The absence of elevated FGF-2 levels in the synovial
fluid at 3 weeks is probably due to the containment of
the transgene product within the spheres and the new
tissue in the defect. This supports the hypothesis of
local growth factor production and action and suggests
that this method of ex vivo gene delivery does not
elicit any undesirable immune response. The decline of
FGF-2 transgene expression in vitro has been recently
demonstrated using a recombinant adeno-associated viral
(rAAV) vector in a similar system [44]. FGF-2 is a secreted
factor that remains mostly attached to its receptor at the
surface of the genetically modified cells. The levels of
FGF-2 might thus be underestimated by the ELISA. A
lack of elevated intraarticular FGF-2 and of inflammatory
changes of the synovial membrane may be advantageous
in a clinical setting, in order to avoid undesired effects
of the therapeutic factor such as observed in synovial
hyperplasia [36,37].
The influence of FGF-2 on the control of cartilage
growth and differentiation during embryogenesis is well
established [9,10]. More recently, therapeutic effects
of FGF-2 protein application on repair of full-thickness
defects have been described [12–15,18]. In a full-
thickness defect model, ex vivo transduced cells containing
a rAAV FGF-2 vector improved cartilage repair when
applied in a type I collagen gel under a periosteal flap
[45]. Alternatively, direct gene delivery of FGF-2 via rAAV
into cartilage defects [26] may prove even more beneficial
[44]. In the present study, differences in articular cartilage
repair were seen as early as 3 weeks post-transplantation.
The improvement of the average total score between 3 and
14 weeks suggests that the effects of FGF-2 remain present
for a period of up to 14 weeks. Although the rabbits were
in their late juvenile stage at the time of implantation and
adult at the time of sacrifice, the intrinsic healing of the
defects was insufficient in this model system, as evidenced
by the high (lower) score values in the lacZ control group
and the presence of degenerative changes after 14 weeks
post-operation. While defects with a diameter larger than
the 3.2 mm employed in the present study may be even
more challenging for cartilage repair, the finding that
articular cartilage regeneration did not occur in the lacZ
control defects suggests that this model system is valid
to investigate articular cartilage repair. Defects of similar
size have been recently employed to study the effect of
overexpression of therapeutic genes on articular cartilage
repair [44,46,47].
The mechanisms by which FGF-2 induces an improved
articular cartilage repair remain to be elucidated. Previous
studies have suggested that FGF-2 mainly acts as a
mitogen for mesenchymal cells including fibroblasts
[5] and chondrocytes [7,8,27]. FGF-2 also stimulates
chemotactic migration of marrow-derived mesenchymal
cells [48] into articular cartilage defects [14], resulting in
a higher cell density. The enhanced filling at 3 weeks
of defects receiving FGF-2 spheres may reflect the
beneficial effect of the therapeutic treatment upon cell
recruitment, while the increased overall repair at 3 weeks
suggests an early stimulating effect on chondrogenesis.
The improvement in the cell morphology parameter
at 14 weeks suggests a long-term effect of FGF-2 on
chondrogenesis. It is possible that overexpression of
FGF-2 may also influence the release of other growth
or transcription factors [49] or the expression of their
receptors [50] in both the transplanted chondrocytes
and the surrounding cells of mesenchymal origin [51].
Analysis of type II collagen expression suggests that, after
3 weeks, FGF-2 may selectively increase type II collagen
content. In contrast, FGF-2 did not lead to an increase in
type I collagen production at both time points.
This gene-based model of localized synthesis of
therapeutic factors may serve as a prototype to examine
the effects of other potentially therapeutic molecules
on articular cartilage repair. In the future, it will
be important to assess the mechanisms of sphere
resorption and to develop approaches to prolong
transgene expression. Likewise, it will be important to test
other therapeutic candidates in order to further enhance
articular cartilage repair. Finally, the long-term durability
of the repair tissue needs to be studied in a larger animal
model that resembles more closely a clinically relevant
situation.
In summary, the results of the present study demon-
strate that localized overexpression of a human FGF-2
gene sequence augments chondrogenesis and enhances
articular cartilage repair in vivo, without adverse effects
on the synovial membrane. These data might be used to
define the effects of genes involved in articular cartilage
repair and lead to the development of novel gene-based
therapies for human articular cartilage defects.
Acknowledgements
We thank T. Thurn and E. Kabiljagic for expert technical assis-
tance, M. Seno for the hFGF-2 cDNA, and K. Remberger for
helpful discussions. Supported by the Deutsche Forschungsge-
meinschaft (DFG MA 2363/1-1, H.M.), the AO ASIF foundation
and NIH grant RO1 AR47702 (S.B.T.).
Copyright  2005 John Wiley & Sons, Ltd. J Gene Med 2006; 8: 100–111.
110 G. Kaul et al.
References
1. O’Driscoll SW. The healing and regeneration of articular
cartilage. J Bone Joint Surg Am 1998; 80: 1795–1812.
2. Hunziker EB. Articular cartilage repair: basic science and
clinical progress. A review of the current status and prospects.
Osteoarthritis Cartilage 2002; 10: 432–463.
3. Shapiro F, Koide S, Glimcher MJ. Cell origin and differentiation
in the repair of full-thickness defects of articular cartilage. J
Bone Joint Surg Am 1993; 75: 532–553.
4. Trippel SB. Growth factors as therapeutic agents. Instr Course
Lect 1997; 46: 473–476.
5. Gospodarowicz D. Localisation of a fibroblast growth factor and
its effect alone and with hydrocortisone on 3T3 cell growth.
Nature 1974; 249: 123–127.
6. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth
factor family of proteins. Annu Rev Biochem 1989; 58: 575–606.
7. Sah RL, Chen AC, Grodzinsky AJ, et al. Differential effects of
bFGF and IGF-I on matrix metabolism in calf and adult bovine
cartilage explants. Arch Biochem Biophys 1994; 308: 137–147.
8. Trippel SB. Growth factor actions on articular cartilage. J
Rheumatol Suppl 1995; 43: 129–132.
9. Schofield JN, Wolpert L. Effect of TGF-beta 1, TGF-beta 2, and
bFGF on chick cartilage and muscle cell differentiation. Exp Cell
Res 1990; 191: 144–148.
10. Kato Y. Roles of fibroblast growth factor and transforming
growth factor-β families in cartilage formation. In Biological
Regulation of the Chondrocytes, Adolphe M (ed). CRC Press:
Boca Raton, 1992; 141–160.
11. Jentzsch KD, Wellmitz G, Heder G, et al. A bovine brain fraction
with fibroblast growth factor activity inducing articular cartilage
regeneration in vivo. Acta Biol Med Ger 1980; 39: 967–971.
12. Otsuka Y, Mizuta H, Takagi K, et al. Requirement of fibroblast
growth factor signaling for regeneration of epiphyseal
morphology in rabbit full-thickness defects of articular cartilage.
Dev Growth Differ 1997; 39: 143–156.
13. Fujimoto E, Ochi M, Kato Y, et al. Beneficial effect of basic
fibroblast growth factor on the repair of full-thickness defects in
rabbit articular cartilage. Arch Orthop Trauma Surg 1999; 119:
139–145.
14. Chuma H, Mizuta H, Kudo S, et al. One day exposure to FGF-2
was sufficient for the regenerative repair of full-thickness defects
of articular cartilage in rabbits.Osteoarthritis Cartilage 2004; 12:
834–842.
15. Mizuta H, Kudo S, Nakamura E, et al. Active proliferation of
mesenchymal cells prior to the chondrogenic repair response in
rabbit full-thickness defects of articular cartilage. Osteoarthritis
Cartilage 2004; 12: 586–596.
16. Yamamoto T, Wakitani S, Imoto K, et al. Fibroblast growth
factor-2 promotes the repair of partial thickness defects of
articular cartilage in immature rabbits but not in mature rabbits.
Osteoarthritis Cartilage 2004; 12: 636–641.
17. Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and
intravenous administration of basic fibroblast growth factor:
vascular and solid organ deposition. Proc Natl Acad Sci U S A
1993; 90: 1513–1517.
18. Shida J, Jingushi S, Izumi T, et al. Basic fibroblast growth factor
stimulates articular cartilage enlargement in young rats in vivo.
J Orthop Res 1996; 14: 265–272.
19. Evans CH, Ghivizzani SC, Robbins PD. Orthopaedic gene
therapy. Clin Orthop 2004; 429: 316–329.
20. Trippel SB, Ghivizzani SC, Nixon AJ. Gene-based approaches for
the repair of articular cartilage. Gene Ther 2004; 11: 351–359.
21. Madry H, Cucchiarini M, Stein U, et al. Sustained transgene
expression in cartilage defects in vivo after transplantation of
articular chondrocytes modified by lipid-mediated gene transfer
in a gel suspension delivery system. J Gene Med 2003; 5:
502–509.
22. Baragi VM, Renkiewicz RR, Qiu L, et al. Transplantation of
adenovirally transduced allogeneic chondrocytes into articular
cartilage defects in vivo. Osteoarthritis Cartilage 1997; 5:
275–282.
23. Ikeda T, Kubo T, Nakanishi T, et al. Ex vivo gene delivery using
an adenovirus vector in treatment for cartilage defects. J
Rheumatol 2000; 27: 990–996.
24. Hirschmann F, Verhoeyen E, Wirth D, et al. Vital marking
of articular chondrocytes by retroviral infection using
green fluorescence protein. Osteoarthritis Cartilage 2002; 10:
109–118.
25. Mierisch CM, Wilson HA, Turner MA, et al. Chondrocyte
transplantation into articular cartilage defects with use of
calcium alginate: the fate of the cells. J Bone Joint Surg Am
2003; 85A: 1757–1767.
26. Madry H, Cucchiarini M, Terwilliger EF, et al. Recombinant
adeno-associated virus vectors efficiently and persistently
transduce chondrocytes in normal and osteoarthritic human
articular cartilage. Hum Gene Ther 2003; 14: 393–402.
27. Madry H, Emkey G, Zurakowski D, et al. Overexpression of
human fibroblast growth factor 2 stimulates cell proliferation
in an ex vivo model of articular chondrocyte transplantation. J
Gene Med 2004; 6: 238–245.
28. Farndale RW, Buttle DJ, Barrett AJ, et al. Improved quantifica-
tion of sulphated glycosaminoglycans by use of dimethylmethy-
lene blue. Biochim Biophys Acta 1986; 883: 173–177.
29. Kiernan JA (ed). Histological and Histochemical Meth-
ods – Theory and Practice, Butterworth-Heinemann: Oxford,
1999.
30. Nixon AJ, Fortier LA, Williams J, et al. Enhanced repair of
extensive articular defects by insulin-like growth factor-I-laden
fibrin composites. J Orthop Res 1999; 17: 475–487.
31. Fortier LA, Mohammed HO, Lust G, et al. Insulin-like growth
factor-I enhances cell-based repair of articular cartilage. J Bone
Joint Surg Br 2002; 84: 276–288.
32. Sellers RS, Peluso D, Morris EA. The effect of recombinant
human bone morphogenetic protein-2 (rhBMP-2) on the healing
of full-thickness defects of articular cartilage. J Bone Joint Surg
Am 1997; 79: 1452–1463.
33. Sellers RS, Zhang R, Glasson SS, et al. Repair of articular
cartilage defects one year after treatment with recombinant
human bone morphogenetic protein-2 (rhBMP-2). J Bone Joint
Surg Am 2000; 82: 151–160.
34. Cuevas P, Burgos J, Baird A. Basic fibroblast growth factor (FGF)
promotes cartilage repair in vivo. Biochem Biophys Res Commun
1988; 156: 611–618.
35. Uteza Y, Rouillot JS, Kobetz A, et al. Intravitreous transplanta-
tion of encapsulated fibroblasts secreting the human fibroblast
growth factor 2 delays photoreceptor cell degeneration in Royal
College of Surgeons rats. Proc Natl Acad Sci U S A 1999; 96:
3126–3131.
36. Qu Z, Huang XN, Ahmadi P, et al. Expression of basic fibroblast
growth factor in synovial tissue from patients with rheumatoid
arthritis and degenerative joint disease. Lab Invest 1995; 73:
339–346.
37. Manabe N, Oda H, Nakamura K, et al. Involvement of fibroblast
growth factor-2 in joint destruction of rheumatoid arthritis
patients. Rheumatology (Oxford) 1999; 38: 714–720.
38. Lim F, Sun AM. Microencapsulated islets as bioartificial
endocrine pancreas. Science 1980; 210: 908–910.
39. Chang PL. Microcapsules as bio-organs for somatic gene therapy.
Ann N Y Acad Sci 1997; 831: 461–473.
40. Soon-Shiong P, Heintz RE, Merideth N, et al. Insulin
independence in a type 1 diabetic patient after encapsulated
islet transplantation. Lancet 1994; 343: 950–961.
41. Bonaventure J, Kadhom N, Cohen-Solal L, et al. Reexpression
of cartilage-specific genes by dedifferentiated human articular
chondrocytes cultured in alginate beads. Exp Cell Res 1994; 212:
97–104.
42. Hauselmann HJ, Masuda K, Hunziker EB, et al. Adult human
chondrocytes cultured in alginate form a matrix similar to native
human articular cartilage. Am J Physiol 1996; 271: C742–752.
43. Rokstad AM, Kulseng B, Strand BL, et al. Transplantation of
alginate microcapsules with proliferating cells in mice: capsular
overgrowth and survival of encapsulated cells of mice and
human origin. Ann N Y Acad Sci 2001; 944: 216–225.
44. Cucchiarini M, Madry H, Ma C, et al. Improved tissue repair
in articular cartilage defects in vivo by rAAV-mediated
overexpression of human fibroblast growth factor 2. Mol Ther
2005; 12: 229–238. DOI: 10.1016/j.ymthe.2005.03.012.
45. Yokoo N, Saito T, Uesugi M, et al. Repair of articular cartilage
defect by autologous transplantation of basic fibroblast growth
factor gene-transduced chondrocytes with adeno-associated
virus vector. Arthritis Rheum 2005; 52: 164–170.
46. Madry H, Kaul G, Cucchiarini M, et al. Enhanced repair of
articular cartilage defects in vivo by transplanted chondrocytes
overexpressing insulin-like growth factor I (IGF-I). Gene Ther
2005; 12: 1171–1179. DOI:10.1038/sj.gt.3302515.
Copyright  2005 John Wiley & Sons, Ltd. J Gene Med 2006; 8: 100–111.
Articular Cartilage Repair by Transplantation of FGF-2 In Vivo 111
47. Mason JM, Breitbart AS, Barcia M, et al. Cartilage and bone
regeneration using gene-enhanced tissue engineering. Clin
Orthop 2000; 379: S171–178.
48. Buckley-Sturrock A, Woodward SC, Senior RM, et al. Differen-
tial stimulation of collagenase and chemotactic activity in
fibroblasts derived from rat wound repair tissue and human
skin by growth factors. J Cell Physiol 1989; 138: 70–78.
49. Murakami S, Kan M, McKeehan WL, et al. Up-regulation of the
chondrogenic Sox9 gene by fibroblast growth factors is mediated
by the mitogen-activated protein kinase pathway. Proc Natl Acad
Sci U S A 2000; 97: 1113–1118.
50. Hernandez-Sanchez C, Werner H, Roberts CT Jr, et al.
Differential regulation of insulin-like growth factor-I
(IGF-I) receptor gene expression by IGF-I and basic
fibroblastic growth factor. J Biol Chem 1997; 272:
4663–4670.
51. Schollmann S, Grugel R, Tatjej D, et al. Basic fibroblast
growth factor modulates the mitogenic potency of
the platelet-derived growth factor (PDGF) isoforms by
specific up-regulation of the PDGF alpha receptor in
vascular smooth muscle cells. J Biol Chem 1992; 267:
18 032–18 039.
Copyright  2005 John Wiley & Sons, Ltd. J Gene Med 2006; 8: 100–111.
